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1  | BACKGROUND
Respiratory syncytial virus (RSV), an acute respiratory viral infection 
which can result in severe disease and death particularly for young in‐
fants, is being increasingly recognized as an important cause of mor‐
bidity and mortality globally. Shi et al have estimated that globally 
RSV‐associated lower respiratory tract infection (LRTI) accounted for 
between 94 600 and 149 400 deaths annually. In addition, 33 mil‐
lion RSV‐associated LRTI resulted in 3.2 million hospital admissions.1 
The authors also describe a higher burden in low‐ and middle‐income 
countries (LMICs) suggesting that these populations may benefit 
most from a future intervention. These estimates, however, have 
some limitations, particularly due to lack of data from several high 
burden areas including sub‐Saharan Africa and limited data in narrow 
age bands for younger children, where the burden is usually highest 
and in whom future interventions are likely to be targeted.
Recently, significant progress has been made in the development 
of a range of RSV vaccine candidates, in particular for the protection 
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Abstract
The World Health Organization (WHO) recently completed the first phase of a RSV 
surveillance pilot study in fourteen countries (two to three in each WHO region) 
building on the Global Influenza Surveillance and Response System (GISRS). This ac‐
tive surveillance strategy had several objectives including understanding RSV‐related 
health burden in a variety of settings. A range of approaches can be used to estimate 
disease burden; most approaches could not be applied by participating countries 
in the WHO surveillance pilot. This article provides the recommendations made by 
WHO for strengthening and expanding the scope of the RSV surveillance in the next 
phase to enable burden estimation.
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of infants via maternal immunization. In addition, new longer acting 
monoclonal antibodies that can protect children for several months 
are in late‐stage clinical development. These developments have ig‐
nited interest in this area. Accurate estimates of RSV‐related health 
burden including costs are needed to undertake economic evalua‐
tions comparing the cost‐effectiveness of alternative interventions.
Ahead of the potential availability of new RSV vaccines for preg‐
nant women and young children and new generation monoclonal 
antibodies and to improve awareness of its importance among policy‐
makers, health staff and the public, the World Health Organization 
(WHO) established an RSV surveillance pilot study in 2017 in four‐
teen countries (two to three in each WHO region) building on the 
Global Influenza Surveillance and Response System (GISRS), hereaf‐
ter referred to as the pilot. The pilot had several objectives including 
contributing to understanding of the health burden of RSV‐related 
infection in a range of settings. This article reviews the potential ap‐
proaches that can be used to estimate disease burden and explores 
their applicability to the WHO RSV surveillance based on the influ‐
enza platform.
2  | DESCRIPTION OF WHO PILOT
The WHO RSV surveillance pilot (1) took place in fourteen countries 
ranging from high to low income and from tropical to temperate set‐
tings. The main aim was to assess whether global RSV surveillance 
could fit into the GISRS platform. A secondary aim was to assess 
the feasibility of collecting data points needed for burden estimates 
in participating countries. The focus of the pilot was to collect data 
to estimate the proportion of respiratory hospitalizations associated 
with RSV. In some settings, this was extended to outpatient or pri‐
mary care settings. Many countries were successful in implementing 
the clinical and laboratory aspects of the surveillance including col‐
lection of the required sample of clinical specimens.
3  | BURDEN OF DISE A SE DUE TO RSV
The burden of disease can be characterized in several different ways. 
Burden on the health service is often quantified in terms of numbers 
of outpatient/primary healthcare consultations; emergency depart‐
ment attendances and hospital admissions. Burden on the popula‐
tion may also be described by the numbers of infections including 
short‐term morbidity and any longer‐term chronic consequences of 
infection plus deaths associated with infection.
Burden of disease estimates may also include the cost of dis‐
eases (either direct costs to the health service or including indirect 
cost to patients and carers due to work loss). For example, a study 
in Bangladesh demonstrated a median direct cost of USD 10 million 
of RSV‐associated hospitalizations among children <5 years of age 
in 2010 and an indirect cost of USD 3 million.2 Better description 
of the health burden due to RSV infection will assist policy‐mak‐
ers to make informed decisions on the allocation of scarce health 
resources when considering new vaccines or other interventions for 
RSV disease.
Obtaining an accurate estimate of the disease‐specific health‐
care burden can be challenging, as often the investigation, labora‐
tory testing and reporting of infectious diseases such as RSV are 
incomplete or absent. RSV‐associated infection is known to be very 
common as shown with ad hoc age‐stratified serological studies, for 
example a study in Kenya indicated that 100% of the population are 
likely to be infected by 3 years of age.3 Only a proportion of these 
infections, however, will be symptomatic and a smaller proportion 
of them will present to health services. In a prospective cohort 
study in Finland, the average annual symptomatic RSV infection rate 
was 275/1000 in children <3 years of age over two RSV seasons, 
of whom 58% developed acute otitis media, and only 3% of those 
symptomatic were hospitalized.4 Outside of enhanced studies such 
as these, most of those with infections that contact the healthcare 
service including hospitalizations will remain untested for RSV. Use 
of routine surveillance data alone without enhanced RSV testing 
may thus significantly underestimate the burden of disease due to 
RSV‐associated LRTI on the healthcare system and on the health of 
the general population.
4  | POTENTIAL METHODS TO 
ME A SURE BURDEN OF DISE A SE USING A 
SURVEILL ANCE PL ATFORM
A range of approaches, many deployed for influenza, can be used to 
estimate local‐, country‐ and international‐level RSV‐related burden 
in terms of numbers of cases and disease incidence either using es‐
tablished disease surveillance systems and vital statistics or through 
special studies. Their potential application in the context of the 
WHO surveillance pilot (1) is explored:
• Method 1: Regression modelling using routine data sources. This 
ecological approach uses national or large‐scale routine labo‐
ratory surveillance and administrative health service data that 
have been collected consistently over several years. It has been 
utilized in some countries to measure the burden of a wide range 
of infections including influenza and RSV.5‐7 Based on weekly 
data on primary care consultations, hospitalizations and deaths 
due to ICD‐coded respiratory disease, the regression model at‐
tributes a proportion of the respiratory infection such as pneu‐
monias and bronchiolitis to RSV (and influenza) using weekly 
laboratory data adjusting for key confounders such as meteoro‐
logical conditions. This statistical approach requires seasonality 
in the infection of interest and health data availability over sev‐
eral years. The method has also been applied to derive interna‐
tional burden estimates for the 2009 influenza pandemic where 
parameter values were used to derive estimates for those coun‐
tries where data were lacking.8 Those WHO pilot countries with 
access to such routine health data could potentially apply such 
methodology.
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• Method 2: Multiplicative modelling. This approach has been applied 
to estimate influenza‐related mortality for the 2009 pandemic by 
multiplying age‐specific symptomatic infection attack rate and 
symptomatic case fatality rate from a range of income settings. 
With this method, a respiratory mortality multiplier was defined to 
consider differences in outcome according to setting. Simulation 
models with these parameters were then applied across all coun‐
tries to derive global estimates of influenza‐related mortality.9 A 
similar approach has been used in a recently published modelling 
study to estimate the global hospital admission rate and mortal‐
ity rate due to RSV‐related acute lower respiratory tract infection 
(ALRI) using information on the proportion of hospital ALRI ad‐
missions that were due to RSV and the case fatality ratio (CFR) 
for RSV‐ALRI.1 However, gaps in RSV knowledge remain. This ar‐
ticle noted that very limited RSV hospital and mortality data were 
available from low‐income settings, particularly in sub‐Saharan 
Africa and the Eastern Mediterranean region. The WHO pilot sur‐
veillance aims to gather relevant hospital surveillance data that 
will strengthen burden estimates, particularly from low‐income 
settings.
• Method 3: Data linkage. Linkage of routine hospital administrative 
data to laboratory records has been used in developed settings 
such as Australia to better describe RSV epidemiology.10 This 
approach can provide more detailed information on patients 
with laboratory‐confirmed RSV, such as prevalence and type of 
underlying risk factors, length of stay and likelihood of different 
outcomes. Estimates of RSV‐related hospital admissions can be 
derived, considering differences in laboratory testing practice 
by age and other key risk factors. These individual‐level data 
allow more accurate cost information to be generated.10,11 To our 
knowledge, few such studies have been undertaken in LMIC set‐
tings and the approach is unlikely to be applicable in most coun‐
tries participating in the WHO pilot surveillance due to lack of 
electronic administrative databases in hospitals or primary care 
settings.
• Method 4: Enhanced surveillance/prospective cohorts. The estab‐
lishment of prospective population cohorts, with the compre‐
hensive systematic collection of epidemiological information and 
biological samples from participants, allows RSV epidemiology 
and burden to be studied more directly—both in the community 
and in primary and secondary care settings. The Influenza and 
RSV in Infants Study (IRIS) is a multi‐country prospective study in 
four low‐income settings and was set up to assess the frequency 
of influenza and RSV in children <1 year of age who have been 
hospitalized and to ascertain predictors of more severe disease.12 
Prospective population‐based studies have also been created, 
including household studies to describe the burden and trans‐
mission of RSV in both low13‐ and high‐income settings.4 Such 
studies can also provide information on key parameters needed 
for realistic transmission models and provide the opportunity to 
gather information on quality of life in young RSV‐positive chil‐
dren, information which at present is largely lacking. At present, 
there are only a very limited number of such studies as they are 
resource intensive to establish and maintain and thus tend to 
cover very limited periods.
• Method 5: Simple, rapid assessment approach. This methodology 
has been used to estimate the national burden of influenza using 
surveillance data from sentinel sites and by applying several ad‐
justments to obtain a national estimate.14‐16 This approach is sim‐
ple and involves using the severe acute respiratory illness (SARI)/
LRTI rate from an established sentinel hospital network, adjusting 
for key risk factors for pneumonia (such as malnutrition, indoor air 
pollution and HIV infection) at the provincial or district level and 
multiplying by the RSV proportion positive from hospital surveil‐
lance to derive the RSV‐associated SARI rate. This was intended 
to be the approach applied in the WHO pilot.
5  | E XPERIENCES IN COLLEC TING 
HOSPITAL AND COMMUNIT Y MORBIDIT Y 
DATA IN THE RSV SURVEILL ANCE PILOT 
AND THE WAY FORWARD IN THE NE X T 
PHA SE
The results of the pilot were reviewed at a face‐to‐face meeting 
(Bangkok, 2018) organized by WHO. Some countries were only able 
to implement a convenience sampling strategy and relied on attend‐
ing physicians to collect samples and baseline clinical information. 
Most of the participating pilot countries lacked data from routine 
hospital admissions, catchment populations and administrative regis‐
ters to estimate the burden of RSV‐associated hospitalization strati‐
fied in different age bands and disaggregated by week or month. This 
meant none of the burden estimation methods outlined above could 
be applied at this first stage of pilot—including method 5.
6  | FUTURE PL ANS
Building on the learning from the pilot, an extension phase is 
planned and coordinated by WHO. Going forward in the next 
phase of the WHO RSV surveillance, countries agreed at a further 
face‐to‐face meeting (Kathmandu, 2019) on the importance of 
prioritizing hospitalization burden associated with RSV in young 
children. The importance of defining a minimum data set was 
identified and that additional efforts would be required to col‐
lect harmonized burden‐related data based on surveillance. Most 
countries proposed the need to set up systems to collect health‐
care attendance data more systematically as part of surveillance 
that could inform policy‐making in circumstances where no data 
from any of the recognized approaches outlined earlier are availa‐
ble in that country. In the absence of resources for special disease 
burden studies, a tiered approach towards disease burden estima‐
tion using surveillance data was proposed for the second phase 
of the WHO surveillance. Table 1 shows the data source for the 
burden‐related variables that are needed to measure the burden 
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estimate, the adjustment factors, the preconditions to avoid bias 
and the limitations and caveats to each of the estimate. The bur‐
den estimates are grouped based on increasing levels of complex‐
ity of collecting data from a sentinel surveillance platform. Tier 1 
groups burden estimates related to proportions of hospitalization 
associated with RSV. Tier 2 groups population‐based incidence 
estimates of hospitalization, ICU‐based burden and mortality 
estimates including case fatality ratio and proportion of hospital 
deaths due to RSV. The third tier refers to national extrapolation 
of population‐based hospitalization incidence rates. Countries 
generally agreed to collect the most basic data (tier 1) required 
to estimate proportions of hospitalization associated with RSV in 
the second phase of the surveillance. Countries with additional 
resources and capacities may opt to use more sophisticated ap‐
proaches for estimation of RSV disease burden (Table 2) including 
the simple rapid assessment approach (method 5) to estimate the 
number of RSV‐related respiratory admissions. Regression model‐
ling methods (method 1) will be possible once an adequate time 
series of these data has been collected, which will allow cross‐ver‐
ification of the rapid assessment method. In addition, some study 
sites may be able to provide independent burden estimates at a 
later stage using one or more of the other methods (methods 2‐4) 
outlined in this paper, which will allow further cross‐validation.
The next phase of the WHO Global RSV surveillance programme 
will assist countries to better describe RSV health burden by collect‐
ing the necessary data needed. The critical data still to be collected 
in phase 2 of the WHO RSV surveillance are as follows: (a) docu‐
mentation of total hospital admissions, respiratory admissions and 
patients screened but not enrolled into the surveillance programme 
and (b) the sampling fractions for cases in different time periods 
during the year. If countries opt for more sophisticated estimates 
of RSV disease burden, information will be additionally required on 
(a) what the catchment population is from which cases are drawn at 
each site (ie how many people would go to the surveillance facility 
if they developed symptoms of an RSV‐like illness), (b) the number 
of in‐referrals from outside the catchment area, (c) catchment pop‐
ulation denominators and (d) Healthcare Utilization Surveys (to esti‐
mate the proportion of catchment population who would present at 
the sentinel facility for an acute respiratory illness).
The WHO RSV surveillance is making important progress to 
estimate RSV‐associated hospital‐related burden in a range of set‐
tings through the inclusion of additional data required to refine 
these estimates. The WHO candidate case definitions for severe 
and very severe RSV‐associated lower respiratory tract infections 
(LRTIs) require additional information on spO2, pulse oximetry and 
IMCI danger signs to be collected, as proxy indicators for disease 
severity.17 These disease severity indicators would allow trends in 
severe RSV disease burden to be monitored following the introduc‐
tion of vaccines. Important steps remain to obtain other health‐re‐
lated data to enable estimates of RSV‐related burden in primary 
care and for mortality. There remains much to be learnt from the 
experiences of measuring influenza burden, which could potentially 
be adapted for RSV.T
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7  | CONCLUSIONS
Accurate in‐country disease burden estimates are important for 
local policy‐makers to make decisions on the introduction of pre‐
vention strategies and to employ cost‐effectiveness models when 
new RSV vaccines or monoclonal antibodies become available. 
Even simple estimates of proportion of hospitalizations associated 
with RSV are important to raise awareness of RSV disease bur‐
den among policy‐makers and providers. The WHO Global RSV 
surveillance programme aims to provide countries with a platform 
based on established approaches to collect these data. The next 
phase of the programme will assist countries with tools for col‐
lection of burden data, closely monitor sampling strategies for 
patient selection and testing, and strengthen the surveillance to 
provide simple, robust burden estimates for informed immuniza‐
tion policy decisions.
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